ImmuPharma seeks deal as regained lupus candidate gets green light for Phase III
This article was originally published in Scrip
Executive Summary
In an update on its lupus drug candidate, ImmuPharma of the UK said it was "in discussions with pharmaceutical companies for a corporate deal regarding Lupuzor" after it was granted both fast track designation and approval to start Phase III development of the product by the US FDA.